Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.
LEARN MORE
Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Research & Development Overview
Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
REAL WORLD EVIDENCE OVERVIEW
Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.
COMMERCIALIZATION OVERVIEW
Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.
COMPLIANCE OVERVIEW
When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.
TECHNOLOGIES OVERVIEWExplore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTSAn in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.
SEE LATEST REPORTS
By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.
LEARN MORE
Building on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.
LEARN MORE
Your new expert analyst is here. Be at the forefront of data-driven decision-making with a new generative AI tool that enables you to interact with our products and solutions like never before. Get results you can trust, faster.
LEARN MORE
The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.
LEARN MORE
The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.
LEARN MORE
IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.
LEARN MORE
Empowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm.
LEARN MOREOur mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.
LEARN MORECareers, culture and everything in between. Find out what’s going on right here, right now.
LEARN MORE
"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.
SEARCH JOBSMedicines have always been used to treat a variety of illnesses but building a detailed understanding of trends at a disease level has consistently remained a challenge. Enhanced forecasting precision, comprehensive competitor analysis and exploration of market trends at the disease level are all better facilitated with IQVIA’s new MIDAS Disease data.
In a series of articles, the latest trends will be investigated across six disease areas using MIDAS Disease insights. The main products and growth drivers will be explored in volume and value terms to provide analysis from different perspectives, leading to an improved understanding of the key market dynamics.
Specifically, this first article will examine the value of the global oncology market, and subsequent articles will focus on the immunology, respiratory, endocrine & metabolic, cardiovascular and central nervous system (CNS) disease areas. The final article will explore the generics sector.
Figure 1: the global 1-year growth rate, 5-year CAGR and total 2022 value of six selected disease areas
Source: IQVIA MIDAS Disease. Sales are global and ex-manufacturer, calculated using a constant exchange rate. Disease area groupings are as in MIDAS Disease, apart from respiratory, where cystic fibrosis has been excluded, and immunology, for which the grouping was created manually. All diseases and products which are unclassified on MIDAS Disease have been excluded from the analysis in these articles.
Figure 1 provides an overview of the historic and recent growth rates of these therapy areas, and their total value in 2020. Of these, the therapy areas which have seen most significant acceleration in growth are endocrine & metabolic, respiratory and CNS.
Widespread innovation means many indications contribute significantly to oncology’s absolute growth
With the greatest 5-year CAGR of these six therapy areas, at 14%, oncology has historically been a leading growth area in the global pharmaceutical market. The last few years have seen much innovation, especially around new, targeted therapies for specific biomarkers and immunotherapies, as explored in the IQVIA white paper In the Eye of the Storm: PD-(L)1 Inhibitors Weathering Turbulence. The value trends in the cancers with the largest share of the oncology market are shown in Figure 2.
Figure 2: trends in sales for the 5 highest-value cancers; sales of the top 6 breast cancer products; market shares of the top 3 indications for two checkpoint inhibitors in 2022
Source: IQVIA MIDAS Disease. Sales are global and ex-manufacturer, calculated using a constant exchange rate. In the first line chart, the value of each cancer is the total value of all its respective products. In the second line chart, the value of each molecule is its value within the breast cancer market only.
The sales of breast cancer therapies are greater than those of any other cancer, worth $26 billion in 2022; breast cancer has maintained this position despite the rise of non-small cell lung cancer (NSCLC) in 2020 and 2021. Within breast cancer, Ibrance (palbociclib) has become the market leader, as shown in Figure 2; meanwhile biosimilars for trastuzumab have entered the market, causing the value of this former market leader to fall.
There are two main products driving absolute growth in the breast cancer market. One of these, Keytruda (pembrolizumab), has already been approved for multiple indications and was notably approved by the FDA for two different forms of triple-negative breast cancer in Q4 2020 and mid-2021. The second driver, Verzenio (abemaciclib), was first approved by the FDA for HR-positive HER2-negative advanced or metastatic breast cancers in 2017 and has since received approval for several other breast cancer indications.
Within the NSCLC market, Keytruda used to be one of two key drivers of absolute growth, and although it remains the clear market leader, its sales have plateaued in recent years. Tagrisso (osimertinib) is now the biggest driver of absolute growth and has the second-largest market share; its sales have been increasing steadily over the last five years, and its 2021-22 year-on-year (YOY) growth rate was 16%.
The value of multiple myeloma has plateaued in the last couple of years, due to recent loss of exclusivity of Velcade (bortezomib), but it remains the indication with the third-largest share of the oncology market.
Other indications with a significant share of the oncology market include prostate and kidney cancer, at 7.6% and 5.6% respectively. Keytruda is one of several drugs driving kidney cancer sales, and with a 2021-22 YOY growth rate of 46% within this indication, it became the joint-biggest drug in kidney cancer in 2022 alongside Opdivo (nivolumab). Liver cancer and bladder cancer are two of the indications within oncology with the greatest growth rates; they had 2021-22 YOY growth rates of 32% and 34% respectively, and even higher 5-year CAGRs of 49% and 36%.
Figure 2 illustrates the split of the sales of two checkpoint inhibitors across their respective top three indications. Over 30% of Keytruda’s value comes from the NSCLC market, followed by several other cancers each with less than 10% of its total value, including kidney cancer. By contrast, Opdivo sales are split more equally across the top three indications, the leader of which is kidney cancer at 22%.
The next article will explore similar trends and insights in the immunology and respiratory markets.
To access additional resources about MIDAS Disease, such as fact sheets, on-demand webinar, blog articles and to inquire about a demo, please click here.
Analyze industry leading sales and medical data in a standardized and comparable way, including cross-country analysis of performance and additional insights into global and regional markets.
Get an up to date view of key performance indicators globally, regionally, or locally.
Be proactive about growing your brand using the latest in data, analytics, and domain expertise.
